Zhu et al. demonstrated in vivo that oral administration of sophoridine (16.9 mg/kg) for 4 weeks increased the expression of the p53, MDM2, LATS-1, and LAST2 proteins and significantly decreased the expression of YAP and CTGF in mice, thus inhibiting the proliferation, invasion, and migration of lung cancer cells (Zhu et al., 2020). Here, TP53 is linked to lung cancer.